Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Head & Neck 1Breast 1

Conditions

Breast Neoplasms 4Hot Flashes 3Sleep Wake Disorders 1Depression 1Carcinoma, Lobular 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Psychiatric Rehabilitation 13Therapeutics 7Early Intervention, Educational 5Yoga 4Surveys and Questionnaires 4Methods 4Saline Solution 3Mindfulness-Based Cognitive Therapy 3Mindfulness 3Esketamine 3Chemotherapy, Adjuvant 3Transcranial Direct Current Stimulation 2Melatonin 2Gabapentin 2Exercise Therapy 2Exercise 2Educational Status 2Counseling 2Control Groups 2Cognitive Behavioral Therapy 2Acupuncture Therapy 2abacavir 1Water 1Venlafaxine Hydrochloride 1Vegetables 1Typhoid-Paratyphoid Vaccines 1Therapeutic Touch 1Tamoxifen 1Stress Mindset Measure 1Sertraline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Depression × Venlafaxine Hydrochloride × Breast × Clear all
NCT00667121 2025-02-14

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

Mayo Clinic

Completed
88 enrolled
Breast

Breast Neoplasms, Depression, Hot Flashes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡